JAMA : the journal of the American Medical Association
-
Randomized Controlled Trial
Effect of Hydrocortisone on Mortality and Organ Support in Patients With Severe COVID-19: The REMAP-CAP COVID-19 Corticosteroid Domain Randomized Clinical Trial.
Evidence regarding corticosteroid use for severe coronavirus disease 2019 (COVID-19) is limited. ⋯ Among patients with severe COVID-19, treatment with a 7-day fixed-dose course of hydrocortisone or shock-dependent dosing of hydrocortisone, compared with no hydrocortisone, resulted in 93% and 80% probabilities of superiority with regard to the odds of improvement in organ support-free days within 21 days. However, the trial was stopped early and no treatment strategy met prespecified criteria for statistical superiority, precluding definitive conclusions.
-
Historical Article
Oral Health in Medicare: Considerations for 21st-Century Coverage.